PD-1/PD-L1 pathway inhibitors, either as monotherapy or combined with chemotherapy, with anti-CTLA4, and with or without bevacizumab, have markedly improved the overall survival (OS) and quality of life of NSCLC patients in different settings [10,11,12,13,14,15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.